Jae Maeng
Research Assistant I, Pharmacology
Education
Bachelor of Arts, Biological Sciences, Vanderbilt University, 2015
Master of Laboratory Investigation, Vanderbilt University, 2018
Research Interests
Joined the Hamm Lab in 2015. Involved in screening of compounds against Protease Activated Receptor 4 (PAR4).
Duvernay MT, Temple KJ, Maeng JG, Blobaum AL, Stauffer SR, Lindsley CW, Hamm HE. Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets. Molecular pharmacology. 2017 Jan;91(1). 39-47.
Temple KJ, Duvernay MT, Maeng JG, Blobaum AL, Stauffer SR, Hamm HE, Lindsley CW. Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles. Bioorganic & medicinal chemistry letters. 2016 Dec 15;26(22). 5481-5486.
Temple KJ, Duvernay MT, Young SE, Wen W, Wu W, Maeng JG, Blobaum AL, Stauffer SR, Hamm HE, Lindsley CW. Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin. Journal of medicinal chemistry. 2016 Aug 25;59(16). 7690-5.